Rif S. El-Mallakh, Ahmed Z. Elmaadawi, Yonglin Gao, Kavita Lohano and R. Jeannie Roberts
Mood Disorders Research Program, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, Kentucky, USA. Corresponding author email: rselma01@louisville.edu

Abstract: Bipolar disorder is a complex condition to treat because agents that may be effective for a specific phase may not be effective for other phases, or may even worsen the overall course of the illness. Over the last decade there has been an increase in research activity in the treatment of bipolar illness. There are now several agents that are well established for the treatment of acute mania (lithium, divalproex, carbamazepine, nearly all antipsychotics), acute bipolar depression (lamotrigine, quetiapine, olanzapine/fluoxetine combination), and relapse prevention (lithium, lamotrigine, divalproex, most second generation antipsychotics). There are also novel treatments that are being studied for all three phases. These include eslicarbazepine, cariprazine, MEM-1003, memantine, tamoxifen and pentazocine for acute mania; pramipexole, modafinil, armodafinil, divalproex, lurasidone, agomelatine, cariprazine, lisedexamfetamine, riluzole, RG-2417, bifeprunox, ropinirole, GSK1014802, and magnetic stimulation for bipolar depression; and asenapine, lurasidone, and cariprazine for relapse prevention. Additionally, there are accumulating data that antidepressants, particularly serotoninergic ones, are not particularly effective in acute bipolar depression and may worsen the course of the illness.

Keywords: Bipolar disorder, treatment, lithium, pramipexole, modafinil, armodafinil, cariprazine.
Introduction
Bipolar disorder is a severe psychiatric illness that can have both good prognosis forms and bad prognosis forms. For a long time research into the course and treatment of bipolar illness had lagged behind advances in the treatment of major depression. In the 1970s and 1980s much of the data garnered for major depressive disorder was simply applied to the treatment of bipolar patients without adequate testing or research. However, beginning in the 1990s, an expansion of bipolar research has well informed clinical care. This expansion of research has led to several established treatments, and some emerging therapies. This paper reviews the current psychopharmacology of bipolar illness, and explores promising treatments currently in development.

Psychopharmacotherapy of mania
Most of the clinical bipolar research effort that has occurred over the past 15 years has been in the treatment of acute mania (Table 1). The majority of the agents currently utilized for acute mania have been studied in double-blind, placebo-controlled, brief (3–4 weeks), multicenter, inpatient studies (Table 1). Some frequently used agents have been studied in randomized, active comparator studies. Most agents that are effective for acute mania are equivalent when studied in head-to-head studies. There is some evidence that patients with euphoric mania do better with lithium,21 while divalproex may be more effective in patients with more depressive symptoms during their manic episode (mixed or dysphoric mania22,23). In general, studies in which an antipsychotic is added to a mood stabilizer (eg, divalproex or lithium), generally show the combination treatment to be superior to mood stabilizer alone.24

In addition to the agents in Table 1, there are several new agents currently being studied for use in acute mania.

Eslicarbazepine (Stedesa™ in the United States; Zebinix®, Exalief® in Europe; chemical name (S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide; development name BIA 2-093) is a new dibenzazepine antiepileptic drug.25 Like most effective mood stabilizing anticonvulsants,26 it is a high affinity antagonist of the voltage-gated sodium channel. Eslicarbazepine is administered as the acetate salt which is rapidly and nearly completely reduced by esterases in the liver to the S enantiomer, S-licarbazepine or eslicarbazepine, which is the active metabolite of oxcarbazepine.25 Eslicarbazepine has similar affinity to inactivated sodium channels (channels in just activated neurons) as carbamazepine, and greater efficacy in animal models of seizure than oxcarbazepine. Studies for bipolar disorder are currently underway but the results are not yet available. However, given the known efficacy of both carbamazepine and oxcarbazepine (Table 1), it is highly likely that eslicarbazepine will also be effective in acute mania.

Table 1. Reasonable options for the treatment of acute mania.

| Agent                  | Approved by FDA | Quality of evidence | Target dose or level | References |
|-----------------------|-----------------|---------------------|----------------------|------------|
| Aripiprazole          | ☒               | A                   | 15–30 mg/day         | 1,2        |
| Asenapine             | ☒               | A                   | 20 mg/day            | 3,4        |
| Carbamazepine & ER   | ☒               | A                   | Levels 8–12 mcg/mL   | 5          |
| Chlorpromazine        | ☒               | B                   | 200–1000 mg/day      | 6          |
| Clonazepam            | ☒               | B                   | 3–6 mg/day           | 7          |
| Divalproex and ER     | ☒               | A                   | Levels 80–150 mcg/mL | 8,9        |
| ECT                   |                 | B                   | Levels 0.6–1.2 mM    | 12         |
| Lithium               | ☒               | A                   | 15–20 mg/day         | 13,14      |
| Olanzapine            | ☒               | A                   | 600–1600 mg/day      | 15         |
| Paliperidone ER       | ☒               | A                   | 3–12 mg/day          | 16         |
| Quetiapine and XR     | ☒               | A                   | 400–600 mg/day       | 17,18      |
| Risperidone           | ☒               | A                   | 1–6 mg/day           | 19         |
| Ziprazidone           | ☒               | A                   | 120–160 mg/day       | 20         |

Notes: A = large, multisite, randomized, blinded, placebo-controlled studies. B = randomized, blinded, active comparator trials. C = small randomized trials, or large naturalistic studies.
Abbreviations: ECT, electroconvulsive therapy; ER, extended release; XR, extended release.
Cariprazine (RGH-188) is an antipsychotic with the profile of D3-preferring dopamine D3/D2 receptor partial agonist. Increased relative affinity for D3 over D2 may confer cariprazine with antipsychotic efficacy as well as the potential for augmented effect on negative and cognitive symptoms of schizophrenia, and fewer extrapyramidal symptoms (EPS). It has been found to be effective in animal models for mania. Monotherapy and add-on to mood stabilizer studies in acute mania are ongoing (http://clinicaltrials.gov/ct2/results?term=bipolar+mania+cariprazine).

MEM-1003 is an L-type calcium channel antagonist that is still in development by Memory Pharmaceuticals. A study of its utility in acute mania has been recently completed, but its results are not available (http://clinicaltrials.gov/ct2/show/NCT00374920?term=mem-1003+bipolar&rank=1). The gene for the α1C subunit of the L-type voltage-gated calcium-channel gene (CACNA1C), located on chromosome 12p13.3, has been associated with bipolar disorder in a genome-wide association study. The L-type calcium channel blockers, verapamil and diltiazem, have been found to be effective in open studies in bipolar disorder, so it is reasonable to examine MEM-1003. However, there is one negative small placebo-controlled trial of verapamil and it was found to be inferior to lithium in a randomized comparison trial, which is why verapamil is not listed in Table 1.

Memantine (Nemenda) is a moderate-affinity, uncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist, approved for moderate to severe Alzheimer’s disease. It reduces manic symptoms in an animal model of mania. In one small (n = 33) open, multicenter study of memantine administered in doses of 20–30 mg/day, 20–30 mg/day, or 30–50 mg/day, all patients improved over the 21 days of the study, but patients receiving 20–30 mg/day had the greatest improvement.

Tamoxifen (Nolvadex, Istubal, Valodex) is an estrogen receptor antagonist that also inhibits protein kinase C (PKC), a mechanism that is shared by both lithium and valproic acid. Tamoxifen antagonizes manic-like behavior in a rat model of mania. As proof of concept, tamoxifen was administered to manic bipolar subjects in small, placebo-controlled double-blind studies as monotherapy and adjunctive to lithium. Despite significant evidence, tamoxifen would only be used in bipolar patients in very unique circumstances. However, these studies do demonstrate the utility of PKC inhibitors as a potentially novel class of antimanic agents.

Pentazocine (Talwin, Fortral) a κ opioid receptor antagonist frequently used for pain control was administered openly to manic patients for a single dose. One hour after administration manic symptoms were significantly reduced. While the authors argue that this may suggest an antimanic effect, it should be remembered that stimulants, such as amphetamine, may also reduce manic symptoms acutely, but these agents are not believed to be antimanic.

**Psychopharmacotherapy of depression**

Bipolar depression is the major clinical challenge in the treatment of bipolar disorder. Depression is more common than either mania or hypomania. However, a series of randomized trials have repeatedly found that antidepressants added to mood stabilizer are not better than mood stabilizer alone. Antidepressants may increase the risk for manic switch, rapid cycling, or a chronic irritable dysphoric state known as antidepressant-associated chronic irritable dysphoria (ACID). For individuals with rapid cycling, antidepressant treatment may increase the risk for future depression. In other words, antidepressants do not appear to be helpful for the treatment of bipolar depression, and may be harmful.

Non-FDA-approved approaches for the treatment of bipolar depression are available (Table 2). Non antidepressant approaches appear to be a better option for the treatment of bipolar depression (Table 2). Optimization of mood stabilizers is a reasonable initial option since all major mood stabilizers have been demonstrated to be useful in bipolar depression (lithium, divalproex, carbamazepine, and lamotrigine). Quetiapine, which is effective for the treatment of mania at doses around 600 mg daily, appears to also be effective for the treatment of acute bipolar depression at doses around 300 mg/day. Long-term two-year studies in which quetiapine is added to either lithium or divalproex find that the combination reduces the risk for relapse some three-fold compared to mood stabilizer alone.

The only other FDA approved treatment for bipolar depression is the olanzapine/fluoxetine combination (Symbiax™). A 24-week open extension found that...
the risk for manic induction due to the coadministration of fluoxetine was low, but 27.4% relapsed into depression.70

Modafanil (Provigil), a non-stimulant agent that is used to increase alertness in subjects with daytime sleepiness due to a variety of conditions, has been tested as an adjunctive agent in depressed bipolar subjects who were randomly assigned to have modafanil (n = 41) or placebo (n = 44) added in a blinded manner.71 Response, defined as at least 50% improvement, was twice as great in modafanil-treated subjects (44%) compared to placebo (23%, P < 0.05).71 In the brief 6 week-study, there was no apparent increase in the manic or hypomanic-induction rate.71 The R-isomer of racemic modafinil, armodafinil, has been examined in depressed type I bipolar patients in a double-blind placebo-controlled, add-on study.72 Despite a high placebo response rate, armodafinil was marginally but significantly superior to placebo.72

Pramipexole (Mirapex), a dopamine agonist, is effective in both type I and type II bipolar patients in two short-term placebo-controlled studies.73,74 Among the two reports, total of 15 with type I and 28 patients with type II were studied over 6 weeks. Response occurred in 60%–67% of patients taking pramipexole and 9%–20% taking placebo.73,74 The 6 week duration of the studies is too brief to determine long term safety, but in a 48 week follow-up of 23 patients (12 with major depression and 11 with bipolar disorder), 27% (two subjects developed hypomania and one developed psychotic mania) experienced a switch.75 This seems like a high rate, but many of the subjects were also receiving antidepressants.

Lurasidone (SM-13496) is a new second generation antipsychotic (SGA) that has just been approved by the FDA for the treatment of acute psychosis in schizophrenia. As with all SGAs, lurasidone has high affinity to the serotonin 5HT_{2A} and dopamine D_{2} receptors. However, unlike most other SGAs, the affinity for the D_{2} receptor is greater than 5HT_{2A}.76 It also has high affinity to 5HT_{1A} receptor and is a partial agonist at the 5HT_{1A} receptor.77 Phase III studies as monotherapy and concomitant treatment with lithium or valproic acid for bipolar depression were started in April 2009 and are known by the acronym PREVAIL (Program to Evaluate Antidepressant Impact of Lurasidone).76 Results have not been reported yet.

Cariprazine at 0.25–0.75 or 1.5–3 mg/day has been studied for bipolar depression in an 8-week, placebo-controlled study that ended in June 2010 (http://clinicaltrials.gov/ct2/show/NCT00852202, accessed 2 January 2011) but its results are not yet available.

Lisdexamfetamine (Vyvance) is FDA approved for attention deficit disorder. It is a prodrug that is slowly metabolized into amphetamine in the blood. Amphetamine78 and methylphenidate79 have both been used for bipolar depression. However, the rate of stimulant-associated mania or hypomania may be as high as 40% in the naturalistic setting80 despite being nonexistent in the setting of acute treatment.79,81 Nonetheless, a double blind, placebo-controlled study of lisdexamfetamine in bipolar depression was started in January 2010 and is ongoing at this point in time (http://clinicaltrials.gov/ct2/show/NCT01093963?cond=Bipolar+Depression%22&rank=18; accessed 14 January 2011).

### Table 2. Reasonable treatment options for the treatment of bipolar depression.

| Agent                | Approved by FDA | Quality of evidence | Target dose or level          | Reference |
|----------------------|-----------------|---------------------|-------------------------------|-----------|
| Bupropion            | C               | 150–450 mg/day      | 53                            |
| Divalproex           | C               | Levels 50–120 ng/mL | 54,55                         |
| Lamotrigine          | A               | 50–400 mg/day       | 57                            |
| Lithium              | B               | Levels 0.6–1.2 mM   | 12                            |
| Methylphenidate      | C               | 10–60 mg/day        | 58,59                         |
| Modafanil            | A               | 100–200 mg/day      | 60                            |
| Olanzapine plus fluoxetine | ✓     | Olanzapine 5–20 mg/day Fluoxetine 20 mg/day | 61,62 |
| Pramipexole          | A               | 0.5–3 mg/day        | 63–65                         |
| Quetiapine           | ✓               | 300 mg/day          | 66                            |

Notes: A = large, multisite, randomized, blinded, placebo-controlled studies. B = randomized, blinded, active comparator trials. C = small randomized trials, or large naturalistic studies.
Riluzole (Rilutek) is a sodium channel antagonist that is approved by the FDA for amyotrophic lateral sclerosis (ALS). It was tested in an open study of 14 patients with bipolar depression who were receiving lithium for at least 4 weeks. Riluzole was added to the lithium and the dose was increased to 100 mg twice daily for an additional 8 weeks. Compared to their baseline, patients improved significantly beginning in week 5 of riluzole treatment. There appeared to be a dose related effect where 66% of those receiving doses at or greater than 200 mg/day responded, but only 33% of those receiving lower doses responded. However, with an annual cost exceeding $4,000 and a nearly impossible prior authorization hurdle, it is unlikely that riluzole will even be studied in larger trials.

RG2417, an oral formulation of uridine, has been investigated its effectiveness in bipolar depression by Repligen. Due to reports of mitochondrial dysfunction in bipolar illness, Uracil is a pyrimidine that is required for RNA synthesis, and is important for mitochondrial function, uridine is ribosylated uracil. None of their findings have been reported in the scientific literature, but business reports show that the drug has had a favorable outcome in phase IIa studies, and is currently undergoing investigation in phase IIb studies. In the original phase IIa study, 83 depressed bipolar patients were given RG2417 for 6 weeks. The improvement in depressive symptoms was quite modest, but was greatest in the most difficult patients—those who had more depressive episodes, suggesting that it may play a role for adjunctive treatment.

Agomelatine is an agonist of melatonin 1 and 2 receptors and an antagonist of serotonin 2C receptors. It is used as an antidepressant in Europe (Valdoxan, Melitor, Thymanax). In a small open add-on study to lithium or valproic acid, agomelatine shows efficacy for bipolar depression. Several other agents have potential to help people with bipolar depression. Bifeprunox is a partial agonist at the dopamine D2 receptors and the serotonin 5-HT1 A receptors (http://peerforum.com/news/bifeprunox-a-partial-agonist-at-dopamine-d2-and-serotonin-5ht1a-receptors-influences-nicotine%e2%80%90seeking-behaviour-in-response-to-drug%e2%80%90associated-stimuli-in-rats—accessed-29-04-2011). It has been studied in phase II in 380 subjects receiving 20–40 mg/day, but data has not been reported (http://clinicaltrials.gov/ct2/show/NCT00134459). Ropinirole (ReQuip) is a D2 agonist that has similarities to pramipexole. It has been reported in case reports to be useful in the treatment of bipolar depression. One placebo-controlled study is currently ongoing in Israel (http://clinicaltrials.gov/ct2/show/NCT00335205). GSK1014802 is a sodium channel antagonist that is currently in phase II studies in bipolar depression (http://clinicaltrials.gov/ct2/show/NCT00908154).

Rapid transcranial magnetic stimulation (TMS) has been approved by the FDA for treatment-resistant depression. In several small studies, mostly open and uncontrolled, TMS has been found to be effective in bipolar depression; one small study finds that slow right-sided stimulation may also be effective. It is likely that future controlled studies will document efficacy of TMS in bipolar depression. This is because reduction in left prefrontal brain activity utilization is shared in both bipolar and unipolar depression, and TMS corrects that abnormality. Unfortunately, there is inadequate data on the duration of the response, and inadequate guidance regarding continuation TMS.

Electroconvulsive therapy (ECT) is an underutilized treatment that effective for both unipolar and bipolar depressed patients who are resistant to pharmacological treatment. Actually, bipolar depression may improve more rapidly than unipolar illness with ultra brief pulse treatment. ECT has also been shown to be effective in bipolar mixed states in which depression and mania coexist. Cognitive complication of ECT can be reduced by utilizing bifrontal (instead of the typical bitemporal) electrode replacement and maintain the same efficacy. However, patient acceptance of ECT remains poor, and use of anesthesia complicates its administration.

Psychopharmacotherapy: relapse prevention

Bipolar disorder is an episodic illness, and the goal of ongoing treatment is the prevention of relapse. There is significant evidence that lithium significantly reduces the risk of relapse, particularly in classic euphoric mania. Despite this, lithium does not have an FDA indication for maintenance treatment in bipolar illness. However, several agents have received
the approval for that indication. In addition to lithium and valproate these include lamotrigine, aripiprazole, olanzapine, risperidone Consta™, and oxcarbazepine as monotherapy, and olanzapine, quetiapine, ziprasidone, and asenapine as add-on agents to lithium or valproate (Table 3).

Divalproex was studied in a 12-months relapse-prevention study. It was a randomized, placebo-controlled, lithium-comparison study, but it was not an enriched design (ie, it did not preferentially recruit patients that had responded to lithium or divalproex).96 Neither lithium nor divalproex separated from placebo in this study. However, a post-hoc subanalysis revealed that patients who had a history of previous good acute response to divalproex had significantly fewer relapses if they remained on divalproex compared to those that were randomized to placebo.97

Oxcarbazepine has been studied in a 52 week randomized assignment comparing its use when added to lithium (n = 26), versus placebo added to lithium (n = 29) in euthymic type I and II bipolar subjects with at least 2 episodes in the previous 12 months. The combination was numerically superior to lithium alone, but none of the parameters reached statistical significance.98 Given the small size of the study, the data actually suggest that oxcarbazepine added to lithium might be superior to lithium alone.98

While long-acting injectable antipsychotics have long been advocated for maintenance treatment in difficult patients,99 it has only been recently that a long-acting injectable antipsychotic has been approved by the FDA for maintenance treatment on bipolar disorder.100 In two placebo-controlled trials with risperidone Consta™, the drug was associated with reduced relapse rates, reduced symptomatic load, and greater time to relapse than both oral medication or placebo injections.100 The effect was driven by the prevention of mania, with minimal effect on the prevention of depression.

Asenapine has been approved for acute treatment of mania, and has been studied in a 40-week extension comparing it with olanzapine as monotherapy.101 Outcome with both active medications was similar.101 Cariprazine is being studied in a 16-week maintenance trial, but data are not yet available (http://clinicaltrials.gov/ct2/show/NCT01059539).

Summary
Clinical bipolar research remains an active field. Pharmaceutical development involves known approaches such as sodium channel antagonists and antipsychotic medications, but also novel approaches that involve mitochondrial pathways and second messengers. None of the agents represent a huge breakthrough in treatment because the pathophysiology of bipolar illness remains unknown. The limited investment in this area of research contributes to the relatively slow rate of progression and the dearth of truly novel approaches with the one exception of TMS.

Most new approaches are variations of the current options. These include several antipsychotic agents (cariprazine and lurasidone), stimulants (lisdexamfetamine), and anticonvulsants (oxcarbazepine and eslicarbazepine). These agents provide additional options without significant additional benefit. It remains unclear whether more novel approaches such as modafinil and armodafinil, pramipexole, riluzole, and memantine, will actually provide a clinical leap for bipolar patients.

Table 3. Reasonable treatment options for relapse and recurrence prevention.

| Agent              | Approved by FDA | Quality of evidence | How used       | Reference |
|--------------------|-----------------|---------------------|----------------|-----------|
| Aripiprazole       | ☑               | A                   | Monotherapy    | 102       |
| Asenapine          | ☑               | A                   | Add-on therapy | 100       |
| Lamotrigine        | ☑               | A                   | Monotherapy    | 103       |
| Lithium            | ☑               | A                   | Levels 0.6–1.2 mM | 12       |
| Olanzapine         | ☑               | A                   | 100–200 mg/day | 105       |
| Oxcarbazepine      | ☑               | A                   | Add on therapy | 97        |
| Quetiapine*        | ☑               | A                   | Add on therapy | 68        |
| Risperidone consta | ☑               | A                   | Monotherapy    | 100       |
| Ziprasidone        | ☑               | A                   | Add on therapy | 104       |

Notes: A = large, multisite, randomized, blinded, placebo-controlled studies. B = randomized, blinded, active comparator trials. C = small randomized trials, or large naturalistic studies.
Additionally, there are access issues with many of the newer medications. TMS is generally not covered by insurance and is quite expensive (generally approximately $10,000 for a 6 week treatment course). Riluzole is similarly extraordinarily expensive. Off label third party approval for such agents as modafinil, armodafinil, pramipexole, or memantine can be difficult or impossible. Eslicarbazepine is not available in the United States. ECT, even with improved techniques, remains stigmatized. Thus, along with newer approaches, administrative changes that reduces hurdles to access will be required.

Nonetheless, over the near future, clinicians can expect their treatment options to expand.

Disclosure
This manuscript has been read and approved by all authors. This paper is unique and is not under consideration by any other publication and has not been published elsewhere. The authors and peer reviewers of this paper report no conflicts of interest. The authors confirm that they have permission to reproduce any copyrighted material.

References
1. Keck PE Jr, Marcus R, Tourkodimitris S, et al; Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003; 160(9):1651–8.
2. Sachs G, Sanchez R, Marcus R, et al; Aripiprazole Study Group. Aripiprazole in the treatment of acute mania or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006; 20(4):536–46.
3. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009; 11(7):673–86. Erratum: Bipolar Disord. 2010;12(3):350.
4. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind placebo-controlled trial. J Affect Disord. 2010;122(1–2):27–38.
5. Weisler RH, Hirschfeld R, Cutler AJ, et al; SPD417 Study Group. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomized, double-blind, placebo-controlled trials. CNS Drugs. 2006;20(3):219–31.
6. Spring G, Schweid D, Gray C, Steinberg J, Horwitz M. A double-blind comparison of lithium and chlorpromazine in the treatment of manic states. Am J Psychiatry. 1970;126(9):1306–10.
7. Edwards R, Stephenson U, Flewett T. Clonazepam in acute mania: a double blind trial. Aust NZ J Psychiatry. 1991;25(2):238–42.
8. Bowden CL, Brugger AM, Swann AC, et al; for the Depakote Mania Study Group. Efficacy of Divalproex vs Lithium and Placebo in the Treatment of Mania. JAMA. 1994;271(12):918–24. Erratum: JAMA. 1994;271(23):1830.
9. Bowden CL, Swann AC, Calabrese JR, et al; Depakote ER Mania Study Group. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry. 2006;67(10):1501–10.
10. Small JG, Klapper MH, Kellams JJ, et al. Electroconvulsive treatment compared with lithium in the management of manic states. Arch Gen Psychiatry. 1988;45(8):727–32.
11. Hirenmani RM, Thirthalli J, Tharayil BS, Gangadhar BN. Double-blind randomized controlled study comparing short-term efficacy of bifrontal and bitemporal electroconvulsive therapy in acute mania. Bipolar Disord. 2008; 10(6):701–7.
12. El-Mallakh RS. Lithium: Actions and Mechanisms. Washington, DC: American Psychiatric Press, 1996.
13. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGGW Study Group. Am J Psychiatry. 1999;156(5):702–9.
14. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry. 2000;57(9):841–9. Erratum: Arch Gen Psychiatry. 2002;59(1):91.
15. Kakkar AK, Relhan HS, Unni KE, Gupta NK, Chopra D, Karatia D. Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study. Eur Psychiatry. 2009;24(3):178–82.
16. Vieta E, Nuaamah IF, Lim P, et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord. 2010;12(3):230–43.
17. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005;66(1):111–21.
18. Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin. 2005;21(6):923–34.
19. Hirschfeld RM, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161(6):1057–65.
20. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K; Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160(4):741–8.
21. Gershon S, Chengappa KN, Malhi GS. Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disord. 2009;11(Suppl 2):34–44.
22. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry. 1992;149(1):108–11.
23. Swann AC, Bowden CL, Morris D, et al. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry. 1997;54(1):37–42.
24. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007;64(4):442–55.
25. Brown ME, El-Mallakh RS. Role of eslicarbazepine in the treatment of bipolar mania and mixed states. Bipolar Disord. 2010;12(3):160(9):1651–8.
26. El-Mallakh RS, Huff MO. Mood stabilizers and ion regulation. Harv Rev Psychiatry. 2001;9:23–32.
27. Kiss B, Horvath A, Nemethy Z, et al. Cariprazine (RGH-188), a dopamine D3 receptor-prefering, D2/D3 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333:328–40.
28. Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today. 2005;10:917–25.
29. Gyertyan I, Saghy K. The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur J Pharmacol. 2007;572:171–4.
30. Adham N, Samoriski G, Gao YL, et al. Cariprazine (RGH-188), a Potential Antipsychotic with Dopamine D2/D3, Functional Antagonist Properties, Attenuates Manic-Like Behaviors in Animal Models. Presented at the Society for Neuroscience, Chicago, Illinois, 17–21 October 2009.
31. Ferreira MA, O’Donovan MC, Meng YA, et al. Collaborative genome-wide association support studies for a role for ANK3 and CACNA1C in bipolar disorder. Nature Genetics. 2008;40(9):1056–8.

32. Casamassima F, Hay AC, Benedetti A, Lattanzi L, Cassano GB, Perlis RH. L-type calcium channels and psychiatric disorders: a brief review. Am J Med Genet B Neuropsychiatr Genet. 2016;158B(8):1373–90.

33. Janicak PG, Sharma RP, Pandey G, Davis JM. Verapamil for the treatment of acute mania: a double-blind, placebo-controlled trial. Am J Psychiatry. 1998;155(7):972–3.

34. Walton SA, Berk M, Brook S. Superiority of lithium over verapamil in acute mania: a randomized, controlled, single-blind trial. J Clin Psychiatry. 1996;57(11):543–6.

35. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist – a review of preclinical data. Neuropharmacology. 1999;38:735–67.

36. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317–24.

37. Gao Y, Payne RS, Schurr A, et al. Memantine reduces mania-like symptoms in animal models. Psychiatry Res. 2011 (in press).

38. Keck PE Jr, Hsu HA, Papadakis K, Russo J Jr. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clin Neuropharmacol. 2009;32(4):199–204.

39. Zarate CA, Manji HK. Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs. 2009;23(7):569–82.

40. Einat H, Yuan P, Szabo ST, Dogra S, Manji HK. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology. 2007;55(3–4):123–31.

41. Zarate CA Jr, Singh JB, Carlson PJ, et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 2007;9(6):561–70. Erratum: Bipolar Disord. 2007;9(8):932.

42. Yildiz A, Guleruyz S, Ankerst DF, Öngür D, Renshaw PF. Protein Kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry. 2008;65(3):253–63.

43. Amrollahi Z, Rezaei F, Salehi B, et al. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord. 2011;129(1–3):327–31.

44. Cohen BM, Murphy B. The effects of pentazocine, a kappa agonist, in patients with mania. Int J Neuropsychopharmacol. 2008;11(2):243–7.

45. Beckman VA, Heinemann H. d-Amphetamine beim manischen Syndrom. Arzneimittelforschung. 1976;26:1135–6.

46. Brown WA, Mueller B. Alleviation of manic symptoms with catecholamine agonists. Am J Psychiatry. 1979;136:230–1.

47. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530–7.

48. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261–9.

49. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar disorder. J Neurol Med. 2007;356(17):1711–22.

50. El-Mallakh RS, Karipot P. Chronic depression in bipolar disorder. J Clin Psychiatry. 2006;67(5):798–806.

51. Ghaemi SN, Gilmer WS, Goldberg JF, et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry. 2007;68(12):1840–4.

52. Bond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord. 2010;124(3):228–34.

53. Muzina DJ, Gao K, Kemp DE, et al. Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2010 Aug 24. [Epub ahead of print].

54. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from two randomised trials. Br J Psychiatry. 2009;194(1):4–9.

55. El-Mallakh RS. An open study of memantine in bipolar depression. Bipolar Disord. 2000;2:56–9.

56. Lydon E, El-Mallakh RS. Naturalistic long-term use of memantine in bipolar disorder. J Clin Psychopharmacol. 2006;26:516–8.

57. Frey MA, Gruenze H, Suppes T, McElroy SL, Keck PE Jr, Walden J, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164:1242–9.

58. Tohen M, Vieta E, Calabrese JR, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079–88. Erratum: Arch Gen Psychiatry. 2004;61(2):176.

59. Corya SA, Perlis RH, Keck PE Jr, Lin DY, Case MG, Williamson DJ, et al. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry. 2006;67(5):798–806.

60. Goldberg JB, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161:564–6.

61. Zorate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004;56:54–60.

62. El-Mallakh RS, Penagalluri P, Kammenni A, Gao Y, Roberts RJ. Long-term use of pramipexole in bipolar depression: A naturalistic retrospective chart review. Psychiatr Q. 2010;81(3):207–13.

63. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010;121(1–2):106–15.

64. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010;121(1–2):106–15.

65. Suppes T, Vieta E, Liu S, Brocher M, Paulsson B. Trial 127 Investigators. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry. 2009;166(4):476–88.

66. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079–88. Erratum: Arch Gen Psychiatry. 2004;61(2):176.

67. El-Mallakh RS, Perlis RH, Keck PE Jr, et al. 2009;23(7):564–6.
Emerging bipolar treatments

74. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. *Biol Psychiatry*. 2004;56: 54–60.

75. Cassano P, Lattanzi L, Soldani F, et al. Pramipexole in treatment-resistant depression: an extended follow-up. *Depress Anxiety*. 2004;20(3):131–8.

76. Anonymous. PREVAIL: Program to Evaluate Antidepressant Impact of.

77. El-Mallakh RS. An open study of methylphenidate in bipolar depression. *Bipolar Disord*. 2000;2:56–9.

78. Wingo AP, Ghaemi SN. Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients. *Psychopharmacol Bull*. 2008;41(4):37–47.

79. Scheffer RE, Kowatch RA, Carmody T, Rush AJ. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. *Am J Psychiatry*. 2005;162(1):58–64.

80. Song JH, Huang CS, Nagata K, Yeh JY, Narashashi T. Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. *J Pharmacol Exp Ther*. 1997;282(2):707–14.

81. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. *N Engl J Med*. 1994;330(9):585–91.

82. Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. *Pharmacopsychiatry*. 2001;34(4):137–41.

83. Cassano P, Lattanzi L, Fava M, et al. Rotipinrole in treatment-resistant depression: a 16-week pilot study. *Can J Psychiatry*. 2005;50(6):357–60.

84. Dell’Osso B, Mundo E, D’Urso N, et al. Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression. *Bipolar Disord*. 2009;11(1):76–81.

86. Bartolucci G, Lanzone F, De Giorgio D, et al. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. *Bipolar Disord*. 2007;9(6):628–35.

87. Tamás RL, Menkes D, El-Mallakh RS. Stimulating research: A prospective, randomized, double-blind, sham-controlled study of slow transcranial magnetic stimulation in depressed bipolar patients. *J Neuropsychiatry Clin Neurosci*. 2007;19(2):198–9.

88. Bench CJ, Frackowiak RS, Dolan RJ. Changes in regional cerebral blood flow on recovery from depression. *Psychol Med*. 1995;25(2):247–61.

89. Hosokawa T, Momose T, Kasai K. Brain glucose metabolism difference between bipolar and unipolar mood disorders in depressed and euthymic states. *Prog Neuropsychopharmacol Biol Psychiatry*. 2009;33(2):243–50.

90. Speer AM, Benson BE, Kimbrell TK, et al. Opposite effects of high and low frequency rTMS on mood in depressed patients: relationship to baseline cerebral activity on PET. *J Affect Disord*. 2009;115(3):386–94.

91. Sienaat P, Vansteelandt K. Demyetnereen K, Peuskens J. Ultra-brief pulse ECT in bipolar and unipolar depressive disorder: differences in speed of response. *Bipolar Disord*. 2009;11(4):418–24.

92. Valenti M, Benabarre A, Garcia-Amador M, Molina O, Bernardo M, Vieta E. Electroconvulsive therapy in the treatment of mixed states in bipolar disorder. *Eur Psychiatry*. 2008;23(1):53–6.

93. Barekta M, Jahangard L, Haghighi M, Ranjkhesh F. Bifrontal versus bitemporal electroconvulsive therapy in severe manic patients. *J ECT*. 2008;24(3):199–202.

94. El-Mallakh RS. Medication compliance and the use of depot neuroleptics in bipolar disorder. *J Psychiatric Pract*. 2007;13(2):79–85.

95. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. *N Engl J Med*. 1994;330(9):585–91.

96. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. *Divalproex Maintenance Study Group. Arch Gen Psychiatry*. 2000;57(5):481–9.

97. Calabrese JR. Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder. *J Affect Disord*. 2008;107(1–3):127–33.

98. El-Mallakh RS. Medication compliance and the use of depot neuroleptics in bipolar disorder. *J Psychiatric Pract*. 2007;13(2):79–85.